Johnson & Johnson $JNJ Stock Position Increased by Robinhood Asset Management LLC

Robinhood Asset Management LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 24.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 42,812 shares of the company’s stock after purchasing an additional 8,428 shares during the period. Robinhood Asset Management LLC’s holdings in Johnson & Johnson were worth $10,873,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in JNJ. Blueline Advisors LLC bought a new position in Johnson & Johnson in the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson during the 4th quarter worth $26,000. Bay Harbor Wealth Management LLC boosted its position in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after acquiring an additional 49 shares during the period. Matrix Trust Co grew its stake in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Johnson & Johnson by 946.7% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company’s stock valued at $32,000 after purchasing an additional 142 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 63,972 shares of company stock valued at $16,245,605 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. TD Cowen raised their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Finally, Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $272.83.

Johnson & Johnson Trading Up 1.6%

Shares of Johnson & Johnson stock opened at $275.63 on Thursday. The business has a fifty day simple moving average of $260.90 and a 200-day simple moving average of $244.61. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The firm has a market cap of $664.25 billion, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 2.59 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: UBS initiated coverage of Johnson & Johnson (JNJ) with a Buy rating and a $320 target, reflecting expectations that the company’s pharmaceutical pipeline can support stronger growth. J&J Jumps as UBS Lifts Its Target to $320
• Positive Sentiment: Healthcare stocks broadly moved higher, with the NYSE Healthcare Index gaining 0.7%, creating a favorable backdrop for JNJ and other defensive healthcare names. Sector Update: Healthcare Stocks Advance Wednesday
• Positive Sentiment: Management will participate in a Deutsche Bank Healthcare Summit fireside chat on September 17. The event could provide additional commentary on the drug pipeline, growth outlook and capital allocation, although no new financial guidance was announced. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.